



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cohort Profile: The West Sweden Asthma Study (WSAS): a multi-disciplinary population-based longitudinal study of asthma, allergy, and respiratory conditions in adults

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027808
Article Type:	Cohort profile
Date Submitted by the Author:	08-Nov-2018
Complete List of Authors:	Nwaru, Bright; University of Gothenburg, Krefting Research Centre Ekerljung, Linda Råding, Madeleine; Goteborgs Universitet, Krefting Research Centre Bjerg, Anders; Goteborgs Universitet, Krefting Research Centre Mincheva, Roxana; Goteborgs Universitet, Krefting Research Centre Malmhäll, Carina; Goteborgs Universitet, Krefting Research Centre Axelsson, Malin; Malmö University, Department of Care Science, Faculty of Health and Society Wennergren, Göran; Goteborgs Universitet, Krefting Research Centre Lotvall, Jan; Lung Pharmacology Group Lundbäck, Bo; Goteborgs Universitet, Krefting Research Centre
Keywords:	adults, Allergy < THORACIC MEDICINE, Asthma < THORACIC MEDICINE, cohort profile, longitudinal cohort, Sweden

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cohort Profile: The West Sweden Asthma Study (WSAS): a multi-disciplinary population-based longitudinal study of asthma, allergy, and respiratory conditions in adults

Bright I Nwaru,^{1,2} Linda Ekerljung,¹ Madeleine Rådinge,¹ Anders Bjerg,¹ Roxana Mincheva,¹ Carina Malmhäll,¹ Malin Axelsson,^{1,3} Göran Wennergren,^{1,4} Jan Lötval,¹ Bo Lundbäck¹

¹Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

²Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, Sweden

³Department of Care Science, Faculty of Health and Society, Malmö University, Sweden

⁴Department of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden

Corresponding author:

Bright Nwaru, PhD,
Krefting Research Centre
Institute of Medicine
University of Gothenburg
P.O. Box 424
SE-405 30 Gothenburg
Sweden
bright.nwaru@gu.se

Keywords: adults, allergy, asthma, cohort profile, longitudinal cohort, Sweden

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES) .

ABSTRACT

Purpose: The West Sweden Asthma Study (WSAS) is a population-representative longitudinal study established to: (1) generate data on prevalence trends, incidence, and remission of asthma, allergy, and respiratory conditions; (2) elucidate on the risk and prognostic factors associated with these diseases; (3) characterise clinically relevant phenotypes of these diseases; and (4) catalyse relevant mechanistic, genomic, genetic, and translational investigations.

Participants: WSAS comprised of randomly selected individuals aged 16-75 years who are followed up longitudinally. The first stage involved a questionnaire survey (>42,000 participants) was undertaken in 2008 and 2016. A random sample (about 8000) of participants in the initial survey undergoes extensive clinical investigations every 8-10 years (first investigations in 2009-2012; second wave currently ongoing). Measurements undertaken at the clinical investigations involve structured interviews, self-completed questionnaire on personality traits, physical measurements, and extensive biological samples.

Findings to date: Some of our key findings have shown a 54% increase in the use of asthma medications between the 1990s and 2000s, primarily driven by a 5-fold increase in the use of inhaled corticosteroids. About 36% of asthmatics expressed at least one sign of severe asthma indicator, with differential lung performance, inflammation, and allergic sensitization among asthmatics with different signs of severe asthma. Multi-symptom asthmatics were at greater risk of having indicators of severe asthma. In all adults, being raised on a farm was associated with a decreased risk of allergic sensitization, rhinitis and eczema, but not asthma. However, among adolescents (i.e. those 16-20 years of age), being raised on a farm decreased the risk of asthma. Personality traits were associated with both beliefs of asthma medication and adherence to treatment.

Future plans: Follow-up of the cohort is being undertaken every 8-10 years. The repeated clinical examinations will take place in 2019-2022. The cohort data are currently being linked to routine Swedish healthcare registers for a continuous follow-up. Mechanistic, genomic, genetic, and translational investigations are ongoing.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study:

- The West Sweden Asthma Study (WSAS) is a large-scale multi-disciplinary population-representative longitudinal study on adult asthma and respiratory health, representing one of the largest of such cohorts in Europe.
- WSAS has several ongoing collaborations with investigators across the Nordic countries, with the OLIN studies, and the FinEsS studies in Finland, Estonia and Sweden and the survey instruments used have been adapted from these ongoing studies.
- With a large sample size, comprehensive measures, and long-term longitudinal design, WSAS provides an opportunity for a continuous generation of contemporary data on the trends in incidence and prevalence of adult asthma and successfully undertaking disease phenotyping.
- With the extensive clinical and molecular investigations being undertaken, WSAS represents one of unique platforms to undertake cutting-edge mechanistic, genomic, genetic, and translational investigations of the underlying pathogenesis of asthma.
- Although the participation rate in WSAS was overall average (with a decline between the surveys in 2008 and 2016), we anticipate, as reflected in current trends in population-based surveys, a continuous decline in response rate over time.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

Introduction

According to the 2015 Global Burden of Disease study, nearly 400 million people live with asthma globally.¹ The report also ranked asthma among the ten causes of disability in 2015, with the disease burden affecting people of all ages, sexes, and races.¹ From the latter half of the last century, the prevalence of asthma was seen to be increasing across different parts of the world.²⁻⁵ Whilst some recent data indicate a levelling off in some parts of the world, particularly in Australia^{2,6,7} and some European countries,^{2,8-14} other evidence suggests a continuing increase in urbanised settings of low- and middle-income countries¹⁵ and some parts of Europe.¹⁶⁻¹⁸ Much of the available data on asthma prevalence trends have however emanated from children and adolescent populations. There are paucity of data on the prevalence trends in adults, particularly data to help elucidate the trends after the 1990s.² Well-designed population-representative long-term longitudinal studies are required to obtain contemporary trends in the prevalence of asthma in adults.

Over the last decade, our understanding of the pathogenesis of asthma has been greatly advancing.^{19,20} Contrary to previous understanding, it is now continuously appreciated that asthma is a complex and heterogeneous syndrome with different underlying distinct phenotypes.¹⁹⁻²³ These phenotypes tend to present with varying clinical pictures, prognosis, risk factors, and response to treatment.²¹⁻²³ Through analyses of several children cohorts, common asthma phenotypes have been characterized, including transient wheezing, non-atopic wheezing, and IgE-mediated wheezing.^{24,25} In contrast, the lack of well-designed population-representative cohorts has meant that far less knowledge has been gained regarding asthma phenotypes in adults. There are today several partly similar suggested groupings of asthma phenotypes in adults; one of the common approaches has been to group them into three: (1) trigger-induced asthma (e.g. occupational asthma, cigarette smoke-induced asthma, exercise-induced asthma); (2) symptom-based asthma (e.g. asthma with persistent airflow limitation, adult-onset asthma, obesity-related asthma); and (3) biomarker-based asthma (e.g. eosinophilic associated asthma).^{22,24,26,27} Adult-onset asthma is different from asthma in childhood^{28,29} and it is less associated with allergy and atopy, but is often associated with obesity, represents more severe disease, has low remission rate, poor prognosis and faster decline in lung function.^{29,30} Definitive phenotyping of adult asthma will engender better insights into the potential disease mechanisms and will help to identify potentially relevant biomarkers that can aid more targeted treatment.^{23,31,32}

The West Sweden Asthma Study (WSAS)¹³ is a large-scale multi-disciplinary population-representative longitudinal study on asthma, which was established in 2008 with the overarching aim of contributing to better understanding of asthma in adults. WSAS has both short- and long-term goals (Figure 1). The short-term goal is to generate data on the trends in prevalence, incidence, and remission of asthma, respiratory conditions, chronic obstructive pulmonary disease (COPD), and allergic diseases in adults in the western Swedish population and to elucidate on the risk and

1 prognostic factors associated with these diseases, as well as the patterns in asthma remission. The
2 long-term goals are to: (1) characterise clinically relevant phenotypes of asthma, allergy and
3 respiratory conditions and perform detailed clinical and molecular epidemiologic investigations of
4 these conditions; and (2) catalyse relevant mechanistic, genomic, genetic, and translational
5 investigations for better understanding of asthma.
6
7
8
9

10
11 **Cohort description**
12

13 *Ethics approval*

14 The study and its sub-studies have been approved by the local Ethics Committee at the University
15 of Gothenburg.
16
17

18
19 *Study population*

20 WSAS involves an initial cross-sectional survey of randomly selected individuals aged 16-75 years
21 who are then subsequently followed up longitudinally (Figure 2).^{13,33} The first survey (WSAS I) was
22 undertaken in 2008 in which a random sample of 30 000 people (representative of the age and sex
23 composition of the study area) were invited. Of these, excluding those who were not traceable
24 (n=782), 18 087 (all 62%; women 67%; men 56%) participated in the study. From the participants, a
25 random sample of 2000 people from all participants and additional 1524 subjects with asthma
26 (altogether 3524 people) were invited to take part in extensive clinical investigations. Of those invited,
27 2006 participated in the clinical investigations, which took place between 2009 and 2012.³³ A second
28 survey (WSAS II) was carried out in 2016 in which a random sample of 50 000 people of the same
29 age group as in WSAS I were invited to take part in the study. The sampling base (areas covered)
30 in WSAS II did not fully overlap with WSAS I; moreover, each survey constitutes different
31 participants. In total, 24 534 (all 50%; women 56%; men 46%) of the 50 000 invited participated in
32 the study. About 2200 of those that participated in WSAS II have current asthma; in addition to these,
33 4000 random sample from all participants (altogether 6200 people) will be invited to take part in the
34 extensive clinical phase of the study. The goal of WSAS II was to study prevalence change and also
35 to expand the overall study base and to enhance the number of participants included in subsequent
36 clinical phases of the study.
37
38
39
40
41
42
43
44
45
46
47

48
49 *Cohort follow-up*

50 Those who participated in WSAS I in 2008 were invited for a follow-up survey in 2016. In addition,
51 those who took part in the clinical investigations between 2009 and 2012 have been invited and are
52 currently undergoing follow-up clinical investigations. Our goal is to capture incident cases of the
53 outcomes, investigate the role of baseline risk factors in disease incidence, and to measure changes
54 in clinical outcomes post-baseline. Continuous follow-up of the cohort will continue, and this is
55 planned to take place at approximately 8-10 years, at which time measurable changes should have
56 occurred in the study population. Those who participated in WSAS II will be similarly followed and
57
58
59
60

investigated as those in WSAS I. We also obtained consent from participants and ethical approval to link the study data to routine healthcare registers for a continuous follow-up. Linkable registers include the National Board of Health and Welfare (register of causes of deaths, hospitalizations, primary healthcare, and medication prescriptions), Statistics Sweden (containing information on demographics), and the Swedish Health Insurance Authority (register of working life, sickness leaves, and retirement).

Data collection

Box 1 contains a summary of the measurements undertaken at different phases of the study. At baseline, participants received a postal self-completed questionnaire that contained questions that have been previously used in the Obstructive Lung Diseases in Northern Sweden (OLIN),^{34,35} the Global Allergy and Asthma European Network (GA²LEN) studies, the FinEsS studies in Finland, Estonia and Sweden,^{36,37} and the European Community Respiratory Health Survey (ECRHS).³⁸ The questionnaire asked questions about asthma, rhinitis, eczema, chronic bronchitis, COPD, emphysema, respiratory symptoms, use of asthma medications, smoking habits, occupation, socio-economic status, airborne occupational, and environmental exposures. At the clinical investigations, a detailed structured interview was conducted, asking questions about presence of asthma, asthma symptoms and exacerbations, use of medications, healthcare use, obstructive and non-obstructive diseases, smoking habits, asthma triggers, virus induced exacerbations, and food intolerance. A self-completed questionnaire was also carried out to assess issues of health psychology, asking questions related to self-efficacy, personality traits, depression and anxiety, and quality of life. The interview is followed by physical examinations including mainly lung function measurements with dynamic spirometry and in sub-samples lung volumes, furthermore bronchial provocation test with methacholine, fraction of exhaled NO, and measurement of various biological and blood samples including allergy testing with specific IgE, and skin prick tests. Other planned measurements will include proteomics, transcriptomics, genomics, genetics, and linkage to Swedish population registers.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Box 1 Main measurements at different phases of the West Sweden Asthma Study

Phase	Measurements
Baseline survey: 2008 (WSAS I); 2016 (WSAS I and WSAS II)	<i>Self-completed questionnaire only:</i> Self-reported asthma, allergy, respiratory symptoms, medication use Self-reported socio-economic status; smoking habits; and airborne, occupational, and environmental exposures
First clinical follow- up: 2009-12; 2018- ongoing	<i>Structured clinical interview and self-administered questionnaire:</i> Questions about asthma, allergy, respiratory symptoms, medication use Other questions about smoking habits, food intolerance; self-efficacy; personality traits; beliefs about asthma medications depression and anxiety; and quality of life <i>Anthropometric measures:</i> height and weight measurements <i>Clinical examinations:</i> Haemoglobin saturation; blood pressure; blood samples; nasal lavage; skin prick test; specific immunoglobulin E; differential cell counts in blood; component resolved diagnostics; body fat; muscle mass; metabolic age (impedance); hand strength with grip pit; forced impulse oscillometry; forced oscillometry technique (small airways); diffusion capacity; functional residual capacity and total lung capacity; dynamic spirometry (Jaeger's Masterscope); methacholine test); exhaled nitric oxide. Other clinical measurements** are: induced sputum, nasal biopsies, nasal swabs for virus determination and bronchoscopy including bronchial biopsies, bronchial lavage and bronchial brushings.
Ongoing/planned: 2019-	Proteomics (conventional proteomics and mass cytometry; CyTOF)** Genomics** Transcriptomics (i.e. RNA and microRNA analysis)** Linkage to national healthcare registers

**Carried out in a sub-population of those that were clinically examined

Findings to date

Population characteristics

Table 1 shows the distribution of baseline background characteristics of the study population by age and sex. Up to the age of 60 years, more females than males had university education in both WSAS I (2008) and WSAS II (2016) surveys. Whilst the proportion of current smokers was higher in females than males in the youngest age group (≤ 30 years) in 2008, the proportion of current smokers was similar between males and females in 2016. Across all age groups, more males than females were exposed to gas and fumes at work place both in 2008 and 2016. The proportion of those raised on a farm was similar between males and females in both surveys and the proportion increased by age. More females than males in both surveys reported that they had a family history of allergy or asthma.

Key findings

By comparing to a previous study performed in the study area in 1990, we determined that whilst the prevalence of most respiratory symptoms, including wheeze, sputum production, and longstanding

cough, substantially decreased by 2008, the prevalence of physician diagnosed asthma (6% in 1990 versus 8% in 2008) remained relatively stable.¹³ However, during the same period, there was a 54% increase in the use of asthma medications, which was primarily driven by a 5-fold (1.5% to 7.7%) increase in the use of inhaled corticosteroids.³³ We have also shown that individuals with multi-symptom asthma (i.e. report of concurrent presence of at least five asthma symptoms, present in 2% of the population) were at greater risk of having morbidity indicators of asthma severity, including lower FEV₁, higher FeNO levels, elevated hyper-responsiveness, nasal blockage, and chronic rhinosinusitis compared to those with less asthma symptoms.^{39,40} By constructing different degrees of asthma severity based on the number of signs of severe asthma indicators, our recent results showed that about 36% of asthmatics expressed at least one sign of severe asthma indicator and that clinical measures of lung performance, inflammation, and allergic sensitization differ among asthmatics with different signs of severe asthma.⁴¹

Based on our risk factor analyses (Table 2), we have shown that female gender (compared to males) was associated with an increased risk of current asthma and eczema, but not allergic rhinitis.⁴¹ Having concomitant family history of asthma and allergic rhinitis (compared no family history of either conditions) was associated with an increased risk of current asthma and allergic rhinitis, but not current eczema.⁴² A family history of allergic rhinitis only was also associated with an increased risk of allergic rhinitis, but not asthma and eczema; a family history of asthma only was not associated with asthma, rhinitis or eczema (Table 2).⁴² Being raised on a farm was associated with a decreased risk of allergic sensitization, allergic rhinitis and eczema,^{42,43,44} whilst it was not associated with asthma among all adults.⁴² However, there was a decreased risk of asthma among adolescents (i.e. those 16-20 years of age).⁴⁵ In that young age group, being raised on a farm significantly reduced the likelihood of using asthma medicine, OR 0.1 (0.02–0.95).⁴⁵ Obese individuals (compared to normal weight) was associated with the risk of asthma and allergic rhinitis, but not eczema.⁴² Having at least one sibling was associated with an increased risk of asthma, but not allergic rhinitis, whereas, having two more siblings was associated with a decreased risk of eczema.⁴² Sensitization to airborne allergens was associated with an increased risk of asthma, allergic rhinitis, and eczema. Finally, exposure to gas, dust or fumes at work place was associated with an increased risk of asthma and eczema, but not allergic rhinitis (Table 2).⁴² The risk factors observed for asthma were similarly seen for aspirin-intolerant and aspirin-tolerant asthma.⁴⁶ We also showed that personality traits were associated with both beliefs of asthma medication and adherence to treatment, which indicate that individual differences are important in efforts to improve adherence.⁴⁷ Ongoing mechanistic studies include analysis of airway and blood samples from well-defined asthma groups where we more specifically investigate the transcriptome profiles (i.e mRNA and microRNA expression). In addition, we are in collaboration the national mass cytometry facility SciLifeLab in Solna, Stockholm, Sweden, to develop a platform with approximately 40 cell surface or intracellular markers that will be analysed from asthmatics samples within WSAS.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations

Nordic countries have had a long tradition of implementing a systematic research approach in understanding chronic diseases and their underlying mechanisms: usually starting from population epidemiological studies to clinical investigations, and further to mechanistic investigations and translation. The establishment of population-wide disease and health registers and excellent and well-characterised longitudinal cohorts involving all age groups, with various social, economic, and biological measurements, has continuously allowed multidisciplinary investigations into different chronic diseases.^{48,49} Some examples of these studies include the Nordic Medical Birth Registers,^{49,50} the Copenhagen City Heart Study,⁵¹ the Hordaland Health Study,⁵² the Obstructive Lung Disease in Northern Sweden (OLIN) Studies,⁵³ and the European Community Respiratory Health Survey,⁵⁴ which are still ongoing, have provided longitudinal data, including on respiratory health, for the past 30-50 years. Now, WSAS, representing one example of these population cohort studies, represents one of the largest population-representative studies on asthma in Europe.

The multidisciplinary nature of WSAS – integrating aspects of population epidemiology, clinical and molecular epidemiology, mechanistic investigations, and various translational research approaches – establishes it as a major platform to significantly advance clearer understanding of adult asthma, respiratory conditions, and allergy and their consequent burden to the society. With the extensive clinical and molecular investigations being undertaken, WSAS represents one of unique platforms to undertake cutting-edge investigations of the underlying pathogenesis of asthma, involving detailed characterisation of the phenotypes, thereby potentially supporting more targeted therapy and personalized clinical decision-making. Both size of the study and comprehensiveness of measurements are of great significance in successful asthma phenotyping. Constituting a random sample of the population, findings from WSAS can be generalized to adult population of western Sweden. The survey instruments and procedures used in WSAS, having being largely adapted from other national and international population and clinical studies across Europe, ensures that the internal validity of the study is greatly enhanced, thus enabling direct comparison of our estimates to the findings from those studies both in time and space.¹⁹ Although the participation rate in WSAS was overall average (with a decline between the survey in 2008 and 2016), current trends in population-based surveys also show a continuous decline in response rate over time.⁵⁵

Collaboration

We welcome discussions from researchers on collaborative projects that will involve the use of WSAS. Currently such collaborations have been established with investigators across the Nordic countries, with the OLIN study, and the FinEsS studies. We are also working towards developing a secure database for hosting data continuously generated from WSAS. The ultimate goal is that, in

due course, with the necessary permission processes in place, collaborators can gain access to the data for research.

Further details

We are working towards developing a full website that will be dedicated to the WSAS, but summarized descriptions are provided at the website of the Krefting Research Centre, University of Gothenburg, which hosts WSAS, at <https://krefting.gu.se/KRC/research>. For the meantime, interested researchers should send their enquiries to: linda.ekerljung@lungall.gu.se; bright.nwaru@gu.se; madeleine.radinger@lungall.gu.se.

Funding

The study is funded by the VBG Group Herman Krefting Foundation on Asthma and Allergy. Additional support has been received mainly from the Swedish Heart Lung Foundation, the health authorities of the West Gothia Region, the Vårdal Foundation, and the Swedish Research Council. The views expressed in this paper are those of the authors and not those of the funders.

Acknowledgments

The authors are grateful to the research assistants/SRNs Helén Törnqvist, Maryanne Raneklint, Lina Rönnebjerg and Lotte Edvardsson, University of Gothenburg, for performing the major part of the data collection and to Eva-Marie Romell for administrative support. BN acknowledges the support of Knut and Alice Wallenberg Foundation and the Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg.

Competing interests

None declared

References

1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries. *Lancet* 2016; 388:1545-1602.
2. Lundbäck B, Backman H, Lötval J, Rönmark E. Is asthma prevalence still increasing? *Expert Rev Respir Med* 2016; 10:39-61.
3. Woolcock AJ. The problem of asthma worldwide. *Eur Respir Rev* 1991; 1:361-68.
4. Lundbäck B. Epidemiology of rhinitis and asthma. *Clin Exp Allergy* 1998; 28(S2):3-10.
5. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UIK trends from 1955 to 2004. *Thorax* 2007; 62:85-90.
6. Robertson CF, Roberts MF, Kappers JH. Asthma prevalence in Melbourne school-children: have we reached the peak? *Med J Aust* 2004; 180:273-76.

7. Toelle BG, Ng K, Belousova E, Salome CN, Peat JK, Marks GB. Prevalence of asthma and allergy in schoolchildren in Belmont, Australia: three cross-sectional surveys over 20 years. *BMJ* 2004; 328:386-7.
8. Devenny A, Wassall H, Ninan T, Omran M, Khan SD, Russell G. Respiratory symptoms and atopy in children in Aberdeen: questionnaire studies of a defined school population repeated over 35 years. *BMJ* 2004; 329:489-90.
9. Ng Man Kwong G, Proctor A, Billings C, et al. Increasing prevalence of asthma diagnosis and symptoms in children is confined to mild symptoms. *Thorax* 2001; 56:312-4.
10. Anderson HR, Ruggles R, Strachan DP, et al. Trends in prevalence of symptoms of asthma, hay fever, and eczema in 12-14 year olds in the British Isles, 1995-2002: questionnaire survey. *BMJ* 2004; 328:1052-3.
11. Braun-Fahrlander C, Gassner M, Grize L, et al. No further increase in asthma, hay fever and atopic sensitization in adolescents living in Switzerland. *Eur Respir J* 2004; 23:407-13.
12. Zöllner IK, Weiland SK, Piechotowski I, et al. No increase in the prevalence of asthma, allergies and atopic sensitization among children in Germany: 1992-2001. *Thorax* 2005; 60:545-8.
13. Lötvalld J, Ekerljung L, Rönmark EP, et al. West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma. *Respir Res* 2009; 10: 94.
14. Hicke-Roberts A, Åberg N, Wennergren G, Hesselmar B. Allergic rhino-conjunctivitis continued to increase in Swedish children up to 2007, but asthma and eczema levelled off from 1991. *Acta Paediatr* 2017; 106:75-80.
15. Ma Y, Zhao J, Ha ZR, Chen Y, Leung TF, Wong GW. Very low prevalence of asthma and allergies in schoolchildren from rural Beijing, China. *Pediatr Pulmonol* 2009; 44:793-9.
16. Backman H, Räisänen P, Hedman L, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016 – results from three population surveys. *Clin Exp Allergy* 2017; 47:1426-35.
17. Kainu A, Pallasaho P, Piirilä P, Lindqvist A, Sovijärvi P, Pietinalho A. Increase in prevalence of physician-diagnosed asthma in Helsinki during the Finnish Asthma Programme: improved recognition of asthma in primary care? A cross-sectional study. *Prim Care Respir J* 2013; 22:64-71.
18. de Marco R, Cappa V, Accordini S, et al. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. *Eur Respir J* 2012; 39:883-92.
19. Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? *J Allergy Clin Immunol* 2011; 128:495-505.
20. Holgate ST. Asthma: a simple concept but in reality a complex disease. *Eur J Clin Invest* 2011; 41:1339-52.
21. Borish L, Culp JA. Asthma: a syndrome composed of heterogeneous diseases. *Ann Allergy Asthma Immunol* 2008; 101:1-8.

22. Hekking PP, Bel EH. Developing and emerging clinical asthma phenotypes. *J Allergy Clin Immunol Pract* 2014; 2:671-80.
23. Siroux V, Garcia-Aymerich. The investigation of asthma phenotypes. *Curr Opin Allergy Clin Immunol* 2011; 11:393-9.
24. Carlsen KCL, Pijnenburg M. Identification of asthma phenotypes in children. *Breathe* 2011; 8:38-44.
25. Stein RT, Martinez FD. Asthma phenotypes in childhood: lessons from an epidemiological approach. *Pediatr Respir Rev* 2004; 5: 155-61.
26. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med* 2010; 181:315-23.
27. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med* 2012; 18:716-25.
28. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. *Lancet* 2010; 376:803-13.
29. de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really different? *Eur Respir Rev* 2013; 22:44-52.
30. Fingleton J, Travers J, Williams M, et al. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. *J Allergy Clin Immunol* 2015; 136:601-9.
31. Rönmark E, Andersson C, Nyström L, Forsberg B, Järholm B, Lundbäck B. Obesity increases the risk for incident asthma among adults. *Eur Respir J* 2005; 25:282-8.
32. Brusselle GG, Kraft M. Trustworthy guidelines on severe asthma thanks for the ERS and ATS. *Eur Respir J* 2014; 43:315-8.
33. Ekerljung L, Bjerg A, Bossios A, et al. Five-fold increase in use of inhaled corticosteroids over 18 years in the general adult population in West Sweden. *Respir Med* 2014; 108:685-93.
34. Rönmark E, Lundbäck B, Jönsson E, Jonsson AC, Lindström M, Sandström T. Incidence of asthma in adults – report from the Obstructive Lung Disease in Northern Sweden Study. *Allergy* 1997; 52:1071-8.
35. Rönmark E, Jönsson E, Lundbäck B. Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study. *Thorax* 1999; 54:611-3.
36. Pallasaho P, Lindström M, Pölluste J, Loit HM, Sovijärvi A, Lundbäck B. Low socio-economic status is a risk factor for respiratory symptoms: a comparison between Finland, Sweden and Estonia. *Int J Tuberc Lung Dis* 2004; 8:1292-300.
37. Lindström M, Kotaniemi J, Jönsson E, Lundbäck B. Smoking, respiratory symptoms, and diseases: a comparative study between northern Sweden and northern Finland: report from the FinEsS study. *Chest* 2001; 119:852-61.
38. Burney PG, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. *Eur Respir J* 1994; 7:954-60.

39. Lötval J, Ekerljung L, Lundbäck B. Multi-symptom asthma is closely related to nasal blockage, rhinorrhea and symptoms of chronic rhinosinusitis-evidence from the West Sweden Asthma Study. *Respir Res* 2010; 11:163.
40. Ekerljung L, Bossios A, Lötval J, et al. Multi-symptom asthma as an indication of disease severity in epidemiology. *Eur Respir J* 2011; 38:825-32.
41. Mincheva R, Ekerljung L, Bossios A, Lundbäck B, Lötval J. High prevalence of severe asthma in a large random population study. *J Allergy Clin Immunol* 2018; 141:2256-64.
42. Rönmark EP, Ekerljung L, Mincheva R, et al. Different risk factor patterns for adult asthma, rhinitis and eczema: results from West Sweden Asthma Study. *Clin Transl Allergy* 2016; 6:28.
43. Eriksson J, Ekerljung L, Lötval J, et al. Growing up on a farm leads to lifelong protection against allergic rhinitis. *Allergy* 2010; 65:1397-403.
44. Bjerg A, Ekerljung L, Eriksson J, et al. Increase in pollen sensitization in Swedish adults and protective effect of keeping animals in childhood. *Clin Exp Allergy* 2016; 46:1328-36.
45. Wennergren G, Ekerljung L, Alm B, Eriksson J, Lötval J, Lundbäck B. Asthma in late adolescence—farm childhood is protective and the prevalence increase has levelled off. *Pediatr Allergy Immunol* 2010; 21:806-13.
46. Eriksson J, Ekerljung L, Bossios A, et al. Aspirin-intolerant asthma in the population: prevalence and important determinants. *Clin Exp Allergy* 2015; 45:211-9.
47. Axelsson M, Cliffordson C, Lundbäck B, Lötval J. The function of medication beliefs as mediators between personality traits and adherence behavior in people with asthma. *Patient Prefer Adherence* 2013; 7:1101-9.
48. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010; 106:86-94.
49. Langhoff-Roos J, Krebs L, Klungsøyr K, et al. The Nordic medical birth registers – a potential goldmine for clinical research. *Acta Obstet Gynecol Scand* 2014; 93:132-7.
50. Gissler M, Louhiala P, Hemminki E. Nordic Medical Birth Registers in epidemiological research. *Eur J Epidemiol* 1997; 13:169-75.
51. Schnohr P, Jensen GB, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study. *Eur Heart J Suppl* 2011; 3:H1-83.
52. Vikse BE, Vollset SE, Tell GS, Refsum H, Iversen BM. Distribution and determinants of serum creatinine in the general population: the Hordaland Health Study. *Scand J Clin Lab Invest* 2004; 64:709-22.
53. Lundbäck B, Nyström L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. *Eur Respir J* 1991; 4:257-66.
54. Burney PG, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. *Eur Respir J* 1994; 7:954-60.

- 1
2 55. Mindell JS, Giampaoli S, Goesswald A, et al. Sample selection, recruitment and
3 participation rates in health examination surveys in Europe – experience from seven
4 national surveys. *BMC Med Res Methodol* 2015; 15:78.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

bmjopen-2018-027808 on 19 June 2019. Downloaded from <http://bmjopen.bmj.com/> on June 11, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).
All rights reserved. No reuse allowed without permission.
This article has been peer-reviewed and published by copyright, including text and data mining, AI training, and similar technologies.





Figure 1. Phases and components of investigations in the West Sweden Asthma Study

WSAS I



WSAS II




Figure 2. Participant flow in the West Sweden Asthma Study

Table 1. Baseline background characteristics of participants in the West Sweden Asthma Study (WSAS) by age and sex

WSAS I**										
	Frequency N = 18087 n (%)		≤30 years n = 3948 n (%)		31-45 years n = 4851 n (%)		46-60 years n = 4956 n (%)		61-75 years n = 4312 n (%)	
	Males n = 8190	Females n = 9897	Males n = 1695	Females n = 2253	Males n = 2169	Females n = 2682	Males n = 2297	Females n = 2659	Males n = 2027	Females n = 2285
Education level										
Less than high school	1817 (22.2)	2226 (22.5)	179 (10.6)	234 (10.4)	151 (7.0)	182 (6.8)	236 (23.6)	568 (21.4)	944 (46.6)	1236 (54.1)
High school	3385 (41.3)	3427 (34.6)	904 (53.3)	1068 (47.4)	1030 (47.5)	1019 (38.0)	950 (40.8)	950 (35.7)	513 (25.3)	384 (16.8)
Tertiary education	2842 (34.7)	4063 (41.1)	568 (33.5)	922 (40.9)	960 (44.3)	1450 (54.1)	1107 (44.1)	1107 (41.6)	531 (26.2)	579 (25.3)
Missing information	146 (1.8)	181 (1.8)	44 (2.6)	29 (1.3)	28 (1.3)	31 (1.2)	11 (1.5)	34 (1.3)	39 (1.9)	86 (3.8)
Smoking status										
Non-smoker	5202 (63.5)	6227 (62.9)	1369 (80.8)	1650 (73.2)	1552 (71.5)	1801 (67.1)	1595 (54.8)	1426 (53.6)	1021 (50.4)	1343 (58.8)
Ex-smoker	1837 (22.4)	2139 (21.6)	97 (5.7)	203 (9.0)	330 (15.2)	497 (18.5)	669 (29.1)	778 (29.3)	741 (36.6)	655 (28.7)
Current smoker	1151 (14.0)	1531 (15.5)	229 (13.5)	400 (17.7)	287 (13.2)	384 (14.3)	669 (16.1)	455 (17.1)	265 (13.1)	287 (12.6)
Occupational exposure to gas, dust and fumes										
No	5587 (68.2)	8551 (86.4)	1250 (73.7)	1939 (86.1)	1498 (69.1)	2283 (85.1)	1531 (66.6)	2279 (85.7)	1306 (64.4)	2035 (89.1)
Yes	2603 (31.8)	1346 (13.6)	445 (26.2)	314 (13.9)	671 (30.9)	399 (14.9)	666 (33.3)	380 (14.3)	721 (35.6)	250 (10.9)
Raised on a farm										
No	7004 (85.5)	8526 (86.2)	1544 (91.1)	2091 (92.8)	1964 (90.5)	2443 (91.1)	1926 (83.8)	2223 (83.6)	1568 (77.4)	1757 (76.9)
Yes	1186 (14.5)	1371 (13.8)	151 (8.9)	162 (7.2)	205 (9.5)	239 (8.9)	471 (16.1)	436 (16.4)	459 (22.6)	528 (23.1)
Family history of allergy										
No	5746 (70.2)	6010 (60.7)	952 (56.2)	1054 (46.8)	1417 (65.3)	1510 (56.3)	1705 (74.2)	1731 (65.1)	1670 (82.4)	1704 (74.6)
Yes	2444 (29.8)	3887 (39.3)	743 (43.8)	1199 (53.2)	752 (34.7)	1172 (43.7)	922 (25.8)	928 (34.9)	357 (17.6)	581 (25.4)
WSAS II										
	Frequency N = 24534 n (%)		≤30 years n = 4209 n (%)		31-45 years n = 5502 n (%)		46-60 years n = 6957 n (%)		61-75 years n = 7866 n (%)	
	Males n = 11204	Females n = 13330	Males n = 1787	Females n = 2422	Males n = 2456	Females n = 3046	Males n = 1135	Females n = 3822	Males n = 3826	Females n = 4040
Education level										
Less than high school	2096 (18.7)	2152 (16.1)	210 (11.7)	220 (9.1)	145 (5.9)	147 (4.8)	448 (14.3)	352 (9.2)	1293 (33.8)	1433 (35.5)

High school	4700 (41.9)	4591 (34.4)	969 (54.2)	1160 (47.9)	944 (38.4)	878 (28.8)	1677 (46.8)	1564 (40.9)	1320 (34.5)	989 (24.5)
Tertiary education	4294 (38.3)	6415 (48.1)	591 (33.1)	1020 (42.1)	1343 (54.7)	1995 (65.5)	1917 (53.0)	1865 (48.8)	1169 (30.5)	1535 (38.0)
Missing information	114 (1.0)	172 (1.3)	17 (1.0)	22 (0.9)	24 (1.0)	26 (0.9)	29 (0.9)	41 (1.1)	44 (1.2)	83 (2.0)
Smoking status										
Non-smoker	7167 (64.0)	8585 (64.4)	1406 (78.7)	1865 (77.0)	1804 (73.5)	2226 (73.1)	2995 (66.8)	2336 (61.1)	1862 (48.7)	2158 (53.4)
Ex-smoker	2725 (24.3)	3109 (23.3)	134 (7.5)	201 (8.3)	376 (15.3)	537 (17.6)	664 (21.2)	974 (25.5)	1551 (40.5)	1397 (34.6)
Current smoker	1312 (11.7)	1636 (12.3)	247 (13.8)	356 (14.7)	276 (11.2)	283 (9.3)	354 (12.0)	512 (13.4)	413 (10.8)	485 (12.0)
Occupational exposure to gas, dust and fumes										
No	8147 (72.7)	11923 (89.4)	1385 (77.5)	2161 (89.2)	1865 (75.9)	2732 (89.7)	3472 (72.0)	3425 (89.6)	2639 (69.0)	3605 (89.2)
Yes	3057 (27.3)	1407 (10.6)	402 (22.5)	261 (10.8)	591 (24.1)	314 (10.3)	1328 (28.0)	397 (10.4)	1187 (31.0)	435 (10.8)
Raised on a farm										
No	9892 (88.3)	11814 (88.6)	1651 (92.4)	2257 (93.2)	2272 (92.5)	2768 (90.9)	3489 (89.8)	3424 (89.6)	3155 (82.5)	3365 (83.3)
Yes	1312 (11.7)	1516 (11.4)	136 (7.6)	165 (6.8)	184 (7.5)	278 (9.1)	401 (10.2)	398 (10.4)	671 (17.5)	675 (16.7)
Family history of allergy										
No	7711 (68.8)	8041 (60.3)	928 (51.9)	1107 (45.7)	1514 (61.6)	1624 (53.3)	2669 (69.5)	2334 (61.1)	3090 (80.8)	6066 (77.1)
Yes	3492 (31.2)	5289 (39.7)	859 (48.1)	1315 (54.3)	942 (38.4)	1422 (46.7)	1170 (30.5)	1488 (38.9)	736 (19.29)	1800 (22.9)

**20 participants had missing information for age and were therefore excluded from age-stratified analyses

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables 2. Key results of risk factors for asthma, allergic rhinitis, and atopic eczema reported from the West Sweden Asthma Study (WSAS I)

Risk factor	Adjusted estimates ¹		
	Current asthma ² OR (95% CI)	Current allergic rhinitis ³ OR (95% CI)	Current eczema ⁴ OR (95% CI)
Female gender ⁵	1.77 (1.15-2.70)	0.91 (0.69-1.21)	1.71 (1.17-2.51)
Family history of asthma and allergic rhinitis ⁵			
None	1	1	1
Asthma only	1.29 (0.55-3.04)	0.61 (0.34-1.10)	1.45 (0.72-2.94)
Allergic rhinitis only	1.16 (0.66-2.03)	2.58 (1.79-3.72)	1.25 (0.77-2.04)
Both asthma and allergic rhinitis	4.33 (2.57-7.30)	2.76 (1.77-4.31)	1.61 (0.94-2.76)
Raised on a farm ^{5,6}	0.96 (0.52-1.77)	0.64 (0.42-0.96)	0.51 (0.27-0.99)
Body mass index			
Normal (20-25 kg/m ²)	1	1	1
Underweight (<20 kg/m ²)	0.95 (0.36-2.55)	1.42 (0.74-2.71)	1.00 (0.44-2.30)
Overweight (25-30 kg/m ²)	1.04 (0.65-1.67)	1.04 (0.77-1.41)	1.02 (0.68-1.54)
Obese (>30 kg/m ²)	1.95 (1.13-3.36)	2.30 (1.53-3.46)	1.34 (0.80-2.24)
Number of siblings			
0	1	1	1
1	3.09 (1.25-7.63)	1.16 (0.74-1.81)	0.72 (0.42-1.24)
2 or more	2.51 (1.02-6.15)	1.15 (0.74-1.79)	0.55 (0.32-0.94)
Allergic sensitization ^{5,7}	4.11 (2.71-6.25)	5.11 (3.77-6.93)	1.26 (0.85-1.85)
Exposure to gas, dust or fumes at work	1.85 (1.20-2.87)	1.03 (0.76-1.41)	2.08 (1.40-3.08)

¹Respective to each outcome, the estimates adjusted for age, gender, family history of asthma and rhinitis, exposure to gas and gas fumes at work place, body mass index, number of siblings, daycare attendance during childhood, and being raised on a farm

²Current asthma was defined as follows: ever had asthma or ever diagnosed with asthma by a physician and at least one of: reported use of asthma medication, or recurrent wheeze, or attacks of shortness of breath during the last 12 months.

³Allergic rhinitis was defined as follows: having had sneezing, runny nose or nasal blocking apart from colds during the last 12 months and having these nasal symptoms occurred simultaneously with itching and running eyes”

⁴Defined as having ever had recurrent itchy rash for at least 6 months and having had itchy rash during the last 12 months

⁵Reported in Rönmark EP et al. Different risk factor patterns for adult asthma, rhinitis and eczema: results from West Sweden Asthma Study. *Clin Transl Allergy* 2016; 6:28.

⁶Reported in Eriksson J, et al. Growing up on a farm leads to lifelong protection against allergic rhinitis. *Allergy* 2010; 65: 1397-1403.

⁷Allergic sensitization defined as serum immunoglobulin E to ImmunoCAP® Phadiatop ≥0.35 KU/1 to at least one of the following 11 airborne allergens: timothy grass, birch, mugwort, olive, parietaria, cat, dog, horse, D. pteronyssinus, D. farinae, and C. herbarum.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

BMJ Open

Cohort Profile: The West Sweden Asthma Study (WSAS): a multi-disciplinary population-based longitudinal study of asthma, allergy, and respiratory conditions in adults

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027808.R1
Article Type:	Cohort profile
Date Submitted by the Author:	13-Mar-2019
Complete List of Authors:	Nwaru, Bright; University of Gothenburg, Krefting Research Centre Ekerljung, Linda; University of Gothenburg, Krefting Research Centre Råding, Madeleine; Goteborgs Universitet, Krefting Research Centre Bjerg, Anders; Goteborgs Universitet, Krefting Research Centre Mincheva, Roxana; Goteborgs Universitet, Krefting Research Centre Malmhäll, Carina; Goteborgs Universitet, Krefting Research Centre Axelsson, Malin; Malmö University, Department of Care Science, Faculty of Health and Society Wennergren, Göran; Goteborgs Universitet, Krefting Research Centre Lotvall, Jan; Lung Pharmacology Group Lundbäck, Bo; Goteborgs Universitet, Krefting Research Centre
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Public health, Respiratory medicine
Keywords:	adults, Allergy < THORACIC MEDICINE, Asthma < THORACIC MEDICINE, cohort profile, longitudinal cohort, Sweden

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

Cohort Profile: The West Sweden Asthma Study (WSAS): a multi-disciplinary population-based longitudinal study of asthma, allergy, and respiratory conditions in adults

Bright I Nwaru,^{1,2} Linda Ekerljung,¹ Madeleine Rådinger,¹ Anders Bjerg,¹ Roxana Mincheva,¹ Carina Malmhäll,¹ Malin Axelsson,^{1,3} Göran Wennergren,^{1,4} Jan Lötval,¹ Bo Lundbäck¹

¹Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

²Wallenberg Centre for Molecular and Translational Medicine, Institute of Medicine, University of Gothenburg, Sweden

³Department of Care Science, Faculty of Health and Society, Malmö University, Sweden

⁴Department of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden

Corresponding author:

Bright Nwaru, PhD,
Krefting Research Centre
Institute of Medicine
University of Gothenburg
P.O. Box 424
SE-405 30 Gothenburg
Sweden
bright.nwaru@gu.se

Keywords: adults, allergy, asthma, cohort profile, longitudinal cohort, Sweden

ABSTRACT

Purpose: The West Sweden Asthma Study (WSAS) is a population-representative longitudinal study established to: (1) generate data on prevalence trends, incidence, and remission of asthma, allergy, and respiratory conditions; (2) elucidate on the risk and prognostic factors associated with these diseases; (3) characterise clinically relevant phenotypes of these diseases; and (4) catalyse relevant mechanistic, genomic, genetic, and translational investigations.

Participants: WSAS comprised of randomly selected individuals aged 16-75 years who are followed up longitudinally. The first stage involved a questionnaire survey (>42,000 participants) was undertaken in 2008 and 2016. A random sample (about 8000) of participants in the initial survey undergoes extensive clinical investigations every 8-10 years (first investigations in 2009-2012; second wave currently ongoing). Measurements undertaken at the clinical investigations involve structured interviews, self-completed questionnaire on personality traits, physical measurements, and extensive biological samples.

Findings to date: Some of our key findings have shown a 54% increase in the use of asthma medications between the 1990s and 2000s, primarily driven by a 5-fold increase in the use of inhaled corticosteroids. About 36% of asthmatics expressed at least one sign of severe asthma indicator, with differential lung performance, inflammation, and allergic sensitization among asthmatics with different signs of severe asthma. Multi-symptom asthmatics were at greater risk of having indicators of severe asthma. In all adults, being raised on a farm was associated with a decreased risk of allergic sensitization, rhinitis and eczema, but not asthma. However, among adolescents (i.e. those 16-20 years of age), being raised on a farm decreased the risk of asthma. Personality traits were associated with both beliefs of asthma medication and adherence to treatment.

Future plans: Follow-up of the cohort is being undertaken every 8-10 years. The repeated clinical examinations will take place in 2019-2022. The cohort data are currently being linked to routine Swedish healthcare registers for a continuous follow-up. Mechanistic, genomic, genetic, and translational investigations are ongoing.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study:

- The West Sweden Asthma Study (WSAS) is a large-scale multi-disciplinary population-representative longitudinal study on adult asthma and respiratory health, representing one of the largest of such cohorts in Europe.
- WSAS has several ongoing collaborations with investigators across the Nordic countries, with the OLIN studies, and the FinEsS studies in Finland, Estonia and Sweden and the survey instruments used have been adapted from these ongoing studies.
- With a large sample size, comprehensive measures, and long-term longitudinal design, WSAS provides an opportunity for a continuous generation of contemporary data on the trends in incidence and prevalence of adult asthma and successfully undertaking disease phenotyping.
- With the extensive clinical and molecular investigations being undertaken, WSAS represents one of unique platforms to undertake cutting-edge mechanistic, genomic, genetic, and translational investigations of the underlying pathogenesis of asthma.
- Although the participation rate in WSAS was overall average (with a decline between the surveys in 2008 and 2016), we anticipate, as reflected in current trends in population-based surveys, a continuous decline in response rate over time.

Introduction

According to the 2015 Global Burden of Disease study, nearly 400 million people across all age groups currently live with asthma globally.¹ The report also ranked asthma among the ten causes of disability in 2015, affecting people of all ages, sexes, and races.¹ From the latter half of the last century, the prevalence of asthma was seen to be increasing across different parts of the world.²⁻⁵ Whilst some recent data indicate a levelling off in some parts of the world, particularly in Australia^{2,6,7} and some European countries,^{2,8-14} other evidence suggests a continuing increase in urbanised settings of low- and middle-income countries¹⁵ and some increase in some parts of Europe, e.g. Finland, Italy, and Sweden.¹⁶⁻¹⁹ Much of the available data on asthma prevalence trends have however emanated from children and adolescent populations. There are paucity of data on the prevalence trends in adults, particularly the trends after the 1990s.² Well-designed population-representative long-term longitudinal studies are required to obtain contemporary trends in the prevalence of asthma in adults.

Over the last decade, our understanding of the pathogenesis of asthma has been greatly advancing.¹⁹⁻²¹ Contrary to previous understanding, it is now continuously appreciated that asthma is a complex and heterogeneous syndrome with different underlying distinct phenotypes.²⁰⁻²⁴ These phenotypes tend to present with varying clinical pictures, prognosis, risk factors, and response to treatment.²²⁻²⁴ Through analyses of several children cohorts, common asthma phenotypes have been characterized, including transient wheezing, non-atopic wheezing, and IgE-mediated wheezing.^{25,26} In contrast, the lack of well-designed population-representative cohorts has meant that far less knowledge has been gained regarding asthma phenotypes in adults. There are today several partly similar suggested groupings of asthma phenotypes in adults; one of the common approaches has been to group them into three: (1) trigger-induced asthma (e.g. occupational asthma, cigarette smoke-induced asthma, exercise-induced asthma); (2) symptom-based asthma (e.g. asthma with persistent airflow limitation, adult-onset asthma, obesity-related asthma); and (3) biomarker-based asthma (e.g. eosinophilic associated asthma).^{23,25,27,28} Adult-onset asthma is different from asthma in childhood^{29,30} and it is less associated with allergy and atopy, but is often associated with obesity, represents more severe disease, has low remission rate, poor prognosis and faster decline in lung function.^{30,31} Definitive phenotyping of adult asthma will engender better insights into the potential disease mechanisms and will help to identify potentially relevant biomarkers that can aid more targeted treatment.^{24,32,33}

The West Sweden Asthma Study (WSAS)¹³ is a large-scale multi-disciplinary population-representative longitudinal study on asthma, which was established in 2008 with the overarching aim of contributing to better understanding of asthma in adults. WSAS has both short- and long-term goals (Figure 1). The short-term goal is to generate data on the trends in prevalence, incidence, and remission of asthma, respiratory conditions, chronic obstructive pulmonary disease (COPD), and

allergic diseases in adults in the western Swedish population and to elucidate on the risk and prognostic factors associated with these diseases, as well as the patterns in asthma remission. The long-term goals are to: (1) characterise clinically relevant phenotypes of asthma, allergy and respiratory conditions and perform detailed clinical and molecular epidemiologic investigations of these conditions; and (2) catalyse relevant mechanistic, genomic, genetic, and translational investigations for better understanding of asthma.

Cohort description

Ethics approval

The study and its sub-studies have been approved by the local Ethics Committee at the University of Gothenburg.

Study population

WSAS involves an initial cross-sectional survey of randomly selected individuals aged 16-75 years who are then subsequently followed up longitudinally (Figure 2).^{13,34} The first survey (WSAS I) was undertaken in 2008 in which a random sample of 30 000 people (representative of the age and sex composition of the study area) were invited. Of the survey participants, excluding those who were not traceable (n=782), 18 087 (all 62%; women 67%; men 56%) participated in the study. From the participants, a random sample of 2000 people from all participants and additional 1524 subjects with asthma (altogether 3524 people) were invited to take part in extensive clinical investigations. Of those invited, 2006 participated in the clinical investigations, which took place between 2009 and 2012.³³ A second survey (WSAS II) was carried out in 2016 in which a random sample of 50 000 people of the same age group as in WSAS I were invited to take part in the study. The sampling base (areas covered) in WSAS II did not fully overlap with WSAS I; moreover, each survey constitutes different participants. In total, 24 534 (all 50%; women 56%; men 46%) of the 50 000 invited participated in the study. About 2200 of those that participated in WSAS II have current asthma; in addition to these, 4000 random sample from all participants (altogether 6200 people) will be invited to take part in the extensive clinical phase of the study. The goal of WSAS II was to study prevalence change and also to expand the overall study base and to enhance the number of participants included in subsequent clinical phases of the study.

Cohort follow-up

Those who participated in WSAS I in 2008 were invited for a follow-up survey in 2016. In addition, those who took part in the clinical investigations between 2009 and 2012 have been invited and are currently undergoing follow-up clinical investigations. Our goal is to capture incident cases of the outcomes, investigate the role of baseline risk factors in disease incidence, and to measure changes in clinical outcomes post-baseline. Continuous follow-up of the cohort will continue, and this is planned to take place at approximately 8-10 years, at which time measurable changes should have

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

occurred in the study population. Those who participated in WSAS II will be similarly followed and investigated as those in WSAS I. We also obtained consent from participants and ethical approval to link the study data to routine healthcare registers for a continuous follow-up. Linkable registers include the National Board of Health and Welfare (register of causes of deaths, hospitalizations, primary healthcare, and medication prescriptions), Statistics Sweden (containing information on demographics), and the Swedish Health Insurance Authority (register of working life, sickness leaves, and retirement).

Data collection

Box 1 contains a summary of the measurements undertaken at different phases of the study. At baseline, participants received a postal self-completed questionnaire that contained questions that have been previously used in the Obstructive Lung Diseases in Northern Sweden (OLIN),^{35,36} the Global Allergy and Asthma European Network (GA²LEN) studies, the FinEsS studies in Finland, Estonia and Sweden,^{37,38} and the European Community Respiratory Health Survey (ECRHS).³⁹ The questions adapted from OLIN and ECRHS focused on asthma, rhinitis, chronic bronchitis/COPD/emphysema, respiratory symptoms, use of asthma medication and potential risk factors, including smoking habits, family history of respiratory diseases, type of occupation, occupational and environmental exposures, co-morbidities, and socio-economic status. The GA²LEN questionnaire was used to add detailed questions about rhinitis and eczema. The applicable sections of the questionnaire were translated into Swedish before use in the study. A sample ECRHS questionnaire is publicly available at <http://www.ecrhs.org/Quests/ECRHSIImainquestionnaire.pdf>. At the clinical investigations, a detailed structured interview is conducted, asking questions about presence of asthma, asthma symptoms and exacerbations, use of medications, healthcare use, obstructive and non-obstructive diseases, smoking habits, asthma triggers, virus induced exacerbations, and food intolerance. A self-completed questionnaire is also carried out to assess issues of health psychology, asking questions related to self-efficacy, personality traits, depression and anxiety, and quality of life. The interview is followed by physical examinations including mainly lung function measurements with dynamic spirometry and in sub-samples lung volumes, furthermore bronchial provocation test with methacholine, fraction of exhaled NO, and measurement of various biological and blood samples including allergy testing with specific IgE, and skin prick tests. Other planned measurements will include proteomics, transcriptomics, genomics, genetics, and linkage to Swedish population registers.

Patient and Public Involvement

There was no patient or public involvement in this study.

Box 1 Main measurements at different phases of the West Sweden Asthma Study

Phase	Measurements
Baseline survey: 2008 (WSAS I); 2016 (WSAS I and WSAS II)	<i>Self-completed questionnaire only:</i> Self-reported asthma, allergy, respiratory symptoms, medication use Self-reported socio-economic status; smoking habits; and airborne, occupational, and environmental exposures
First clinical follow-up: 2009-12; 2018-ongoing	<i>Structured clinical interview and self-administered questionnaire:</i> Questions about asthma, allergy, respiratory symptoms, medication use Other questions about smoking habits, food intolerance; self-efficacy; personality traits; beliefs about asthma medications depression and anxiety; and quality of life <i>Anthropometric measures:</i> height and weight measurements <i>Clinical examinations:</i> Haemoglobin saturation; blood pressure; blood samples; nasal lavage; skin prick test; specific immunoglobulin E; differential cell counts in blood; component resolved diagnostics; body fat; muscle mass; metabolic age (impedance); hand strength with grip pit; forced impulse oscillometry; forced oscillometry technique (small airways); diffusion capacity; functional residual capacity and total lung capacity; dynamic spirometry (Jaeger's Masterscope); methacholine test); exhaled nitric oxide. Other clinical measurements** are: induced sputum, nasal biopsies, nasal swabs for virus determination and bronchoscopy including bronchial biopsies, bronchial lavage and bronchial brushings.
Ongoing/planned: 2019-	Proteomics (conventional proteomics and mass cytometry; CyTOF)** Genomics** Transcriptomics (i.e. RNA and microRNA analysis)** Linkage to national healthcare registers

**Carried out in a sub-population of those that were clinically examined

Findings to date

Population characteristics

Table 1 shows the distribution of baseline background characteristics of the study population by age and sex. Up to the age of 60 years, more females than males had university education in both WSAS I (2008) and WSAS II (2016) surveys. Whilst the proportion of current smokers was higher in females than males in the youngest age group (≤ 30 years) in 2008, the proportion of current smokers was similar between males and females in 2016. Across all age groups, more males than females were exposed to gas and fumes at work place both in 2008 and 2016. The proportion of those raised on a farm was similar between males and females in both surveys and the proportion increased by age. More females than males in both surveys reported that they had a family history of allergy or asthma.

Key findings

The following findings are based only in WSAS I as analyses of WSAS II are currently ongoing. The following constitute the definitions used for the respective outcomes for which findings are reported

below: *Physician diagnosed asthma* was defined based on a positive response to the question: “Have you been diagnosed as having asthma by a doctor?” *Current asthma* was defined as ever had asthma or diagnosed with asthma by a doctor and at least 1 of the following: reported use of asthma medication, or recurrent wheeze, or attacks of shortness of breath during the last 12 months. *Current allergic rhinitis* was defined as having had sneezing, runny nose, or nasal blocking apart from colds during the last 12 months and having these nasal symptoms occurring simultaneously with itching and running eyes. The definitions of eczema, which we have previously used,⁴⁰ were based on answers to the following questions: *Itchy rash*: ‘Have you ever had an itchy rash which was coming and going for at least six months?’ *Hand eczema only*: ‘Does this (itchy rash) only affect your hands?’ *Current atopic eczema*: ‘Have you had this itchy rash in the last 12 months?’ *Eczema ever*: ‘Have you ever had eczema or any kind of skin allergy?’ By comparing to a previous study performed in the study area in 1990, we determined that whilst the prevalence of most respiratory symptoms, including wheeze, sputum production, and longstanding cough, substantially decreased by 2008, the prevalence of physician diagnosed asthma (6% in 1990 versus 8% in 2008) remained relatively stable.¹³ However, during the same period, there was a 54% increase in the use of asthma medications, which was primarily driven by a 5-fold (1.5% to 7.7%) increase in the use of inhaled corticosteroids.³⁴ We have also shown that individuals with multi-symptom asthma (i.e. report of concurrent presence of at least five asthma symptoms, present in 2% of the population) were at greater risk of having morbidity indicators of asthma severity, including lower FEV₁, higher FeNO levels, elevated hyper-responsiveness, nasal blockage, and chronic rhinosinusitis compared to those with less asthma symptoms.^{41,42} By constructing different degrees of asthma severity based on the number of signs of severe asthma indicators, our recent results showed that about 36% of asthmatics expressed at least one sign of severe asthma indicator and that clinical measures of lung performance, inflammation, and allergic sensitization differ among asthmatics with different signs of severe asthma.⁴³

Based on our risk factor analyses (Table 2) of WSAS I only (analyses of WSAS II are ongoing and not included in these results), we have shown that female gender (compared to males) was associated with an increased risk of current asthma and eczema, but not allergic rhinitis.⁴³ Having concomitant family history of asthma and allergic rhinitis (compared no family history of either conditions) was associated with an increased risk of current asthma and allergic rhinitis, but not current eczema.⁴⁴ A family history of allergic rhinitis only was also associated with an increased risk of allergic rhinitis, but not asthma and eczema; a family history of asthma only was not associated with asthma, rhinitis or eczema (Table 2).⁴⁴ Being raised on a farm was associated with a decreased risk of allergic sensitization, allergic rhinitis and eczema;⁴⁴⁻⁴⁶ whilst it was not associated with asthma among all adults.⁴⁴ However, there was a decreased risk of asthma among adolescents (i.e. those 16-20 years of age).⁴⁷ In that young age group, being raised on a farm significantly reduced the likelihood of using asthma medicine, OR 0.1 (0.02–0.95).⁴⁷ Obese individuals (compared to normal

weight) was associated with the risk of asthma and allergic rhinitis, but not eczema.⁴⁴ Having at least one sibling was associated with an increased risk of asthma, but not allergic rhinitis, whereas, having two more siblings was associated with a decreased risk of eczema.⁴⁴ The strongest risk factor for eczema was family history of both asthma and allergy.⁴⁰ Sensitization to airborne allergens was associated with an increased risk of asthma, allergic rhinitis, and eczema. Finally, exposure to gas, dust or fumes at work place was associated with an increased risk of asthma and eczema, but not allergic rhinitis (Table 2).⁴⁴ The risk factors observed for asthma were similarly seen for aspirin-intolerant and aspirin-tolerant asthma.⁴⁸ We also showed that personality traits were associated with both beliefs of asthma medication and adherence to treatment, which indicate that individual differences are important in efforts to improve adherence.⁴⁹ Ongoing mechanistic studies include analysis of airway and blood samples from well-defined asthma groups where we more specifically investigate the transcriptome profiles (i.e mRNA and microRNA expression). In addition, we are in collaboration the national mass cytometry facility SciLifeLab in Solna, Stockholm, Sweden, to develop a platform with approximately 40-cell surface or intracellular markers that will be analysed from asthmatics samples within WSAS.

Strengths and limitations

Nordic countries have had a long tradition of implementing a systematic research approach in understanding chronic diseases and their underlying mechanisms: usually starting from population epidemiological studies to clinical investigations, and further to mechanistic investigations and translation. The establishment of population-wide disease and health registers and excellent and well-characterised longitudinal cohorts involving all age groups, with various social, economic, and biological measurements, has continuously allowed multidisciplinary investigations into different chronic diseases.^{50,51} Some examples of these studies include the Nordic Medical Birth Registers,^{51,52} the Copenhagen City Heart Study,⁵³ the Hordaland Health Study,⁵⁴ the Obstructive Lung Disease in Northern Sweden (OLIN) Studies,⁵⁵ and the European Community Respiratory Health Survey,⁵⁶ which are still ongoing, have provided longitudinal data, including on respiratory health, for the past 30-50 years. Now, WSAS, representing one example of these population cohort studies, represents one of the largest population-representative studies on asthma in Europe.

The multidisciplinary nature of WSAS – integrating aspects of population epidemiology, clinical and molecular epidemiology, mechanistic investigations, and various translational research approaches – establishes it as a major platform to significantly advance clearer understanding of adult asthma, respiratory conditions, and allergy and their consequent burden to the society. With the extensive clinical and molecular investigations being undertaken, WSAS represents one of unique platforms to undertake cutting-edge investigations of the underlying pathogenesis of asthma, involving detailed characterisation of the phenotypes, thereby potentially supporting more targeted therapy and personalized clinical decision-making. Both size of the study and comprehensiveness of

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

measurements are of great significance in successful asthma phenotyping. Constituting a random sample of the population, findings from WSAS can be generalized to adult population of western Sweden. The survey instruments and procedures used in WSAS, having being largely adapted from other national and international population and clinical studies across Europe, ensures that the internal validity of the study is greatly enhanced, thus enabling direct comparison of our estimates to the findings from those studies both in time and space.²⁰ The main limitation of this study is the anticipated decline in participation rate over time. Although the participation rate in WSAS was overall average (with a decline between the survey in 2008 and 2016), current trends in population-based surveys also show a continuous decline in response rate over time.⁵⁷ Furthermore, as the study primarily focused on asthma, clinical examination of the nose and skin was not performed.

Collaboration

We welcome discussions from researchers on collaborative projects that will involve the use of WSAS. Currently such collaborations have been established with investigators across the Nordic countries, with the OLIN study, and the FinEsS studies. We are also working towards developing a secure database for hosting data continuously generated from WSAS. The ultimate goal is that, in due course, with the necessary permission processes in place, collaborators can gain access to the data for research.

Contributorship statement

Designed the study (BL, JL, LE). Responsible for the study database (LE, BN, MR). Participated in data collection (BL, JL, LE, MR, RM, GW, CM, MA, AB). Planned and executed the statistical analyses and drafted the manuscript (BN, BL, LE, RM, GW, AB). All authors participated in data interpretation, writing of the manuscript and review the data presented. All authors approved the final manuscript.

Data availability statement

Data collection is still ongoing and cannot be shared at the moment. Please contacts below for those would want to know more about the study and would like to collaborate.

Further details

We are working towards developing a full website that will be dedicated to the WSAS, but summarized descriptions are provided at the website of the Krefting Research Centre, University of Gothenburg, which hosts WSAS, at <https://krefting.gu.se/KRC/research>. For the meantime, interested researchers should send their enquiries to: linda.ekerljung@lungall.gu.se; bright.nwaru@gu.se; madeleine.radinger@lungall.gu.se.

Funding

1
2 365 The study is funded by the VBG Group Herman Krefting Foundation on Asthma and Allergy.
3 366 Additional support has been received mainly from the Swedish Heart Lung Foundation, the health
4 367 authorities of the West Gothia Region, the Vårdal Foundation, and the Swedish Research Council.
5 368 The views expressed in this paper are those of the authors and not those of the funders.
6
7 369

8
9
10 370 **Acknowledgments**

11 371 The authors are grateful to the research assistants/SRNs Helén Törnqvist, Maryanne Raneklint, Lina
12 372 Rönneberg and Lotte Edvardsson, University of Gothenburg, for performing the major part of the
13 373 data collection and to Eva-Marie Romell for administrative support. BN acknowledges the support of
14 374 Knut and Alice Wallenberg Foundation and the Wallenberg Centre for Molecular and Translational
15 375 Medicine, University of Gothenburg.
16 376

17
18 377 **Competing interests**

19 378 None declared
20
21 379

22
23 380 **References**

24 381 1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and
25 382 national incidence, prevalence, and years lived with disability for 310 diseases and injuries.
26 383 *Lancet* 2016; 388:1545-1602.
27 384 2. Lundbäck B, Backman H, Lötvall J, Rönmark E. Is asthma prevalence still increasing? *Expert*
28 385 *Rev Respir Med* 2016; 10:39-61.
29 386 3. Woolcock AJ. The problem of asthma worldwide. *Eur Respir Rev* 1991; 1:361-68.
30 387 4. Lundbäck B. Epidemiology of rhinitis and asthma. *Clin Exp Allergy* 1998; 28(S2):3-10.
31 388 5. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UIK trends from 1955
32 389 to 2004. *Thorax* 2007; 62:85-90.
33 390 6. Robertson CF, Roberts MF, Kappers JH. Asthma prevalence in Melbourne school-children:
34 391 have we reached the peak? *Med J Aust* 2004; 180:273-76.
35 392 7. Toelle BG, Ng K, Belousova E, Salome CN, Peat JK, Marks GB. Prevalence of asthma and
36 393 allergy in schoolchildren in Belmont, Australia: three cross-sectional surveys over 20 years.
37 394 *BMJ* 2004; 328:386-7.
38 395 8. Devenny A, Wassall H, Ninan T, Omran M, Khan SD, Russell G. Respiratory symptoms and
39 396 atopy in children in Aberdeen: questionnaire studies of a defined school population repeated
40 397 over 35 years. *BMJ* 2004; 329:489-90.
41 398 9. Ng Man Kwong G, Proctor A, Billings C, et al, Increasing prevalence of asthma diagnosis
42 399 and symptoms in children is confined to mild symptoms. *Thorax* 2001; 56:312-4.
43 400 10. Anderson HR, Ruggles R, Strachan DP, et al. Trends in prevalence of symptoms of asthma,
44 401 hay fever, and eczema in 12-14 year olds in the British Isles, 1995-2002: questionnaire
45 402 survey. *BMJ* 2004; 328:1052-3.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

11. Braun-Fahrlander C, Gassner M, Grize L, et al. No further increase in asthma, hay fever and atopic sensitization in adolescents living in Switzerland. *Eur Respir J* 2004; 23:407-13.
12. Zöllner IK, Weiland SK, Piechotowski I, et al. No increase in the prevalence of asthma, allergies and atopic sensitization among children in Germany: 1992-2001. *Thorax* 2005; 60:545-8.
13. Lötvalld J, Ekerljung L, Rönmark EP, et al. West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma. *Respir Res* 2009; 10: 94.
14. Hicke-Roberts A, Åberg N, Wennergren G, Hesselmar B. Allergic rhino-conjunctivitis continued to increase in Swedish children up to 2007, but asthma and eczema levelled off from 1991. *Acta Paediatr* 2017; 106:75-80.
15. Ma Y, Zhao J, Ha ZR, Chen Y, Leung TF, Wong GW. Very low prevalence of asthma and allergies in schoolchildren from rural Beijing, China. *Pediatr Pulmonol* 2009; 44:793-9.
16. Backman H, Räisänen P, Hedman L, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016 – results from three population surveys. *Clin Exp Allergy* 2017; 47:1426-35.
17. Kainu A, Pallasaho P, Piirilä P, Lindqvist A, Sovijärvi P, Pietinalho A. Increase in prevalence of physician-diagnosed asthma in Helsinki during the Finnish Asthma Programme: improved recognition of asthma in primary care? A cross-sectional study. *Prim Care Respir J* 2013; 22:64-71.
18. de Marco R, Cappa V, Accordini S, et al. Trends in the prevalence of asthma and allergic rhinitis in Italy between 1991 and 2010. *Eur Respir J* 2012; 39:883-92.
19. Borna E, Nwaru BI, Bjerg A, Mincheva R, Rådinger M, Lundbäck B, et al. Changes in the prevalence of asthma and respiratory symptoms in western Sweden between 2008 and 2016. *Allergy*. In press.
20. Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? *J Allergy Clin Immunol* 2011; 128:495-505.
21. Holgate ST. Asthma: a simple concept but in reality a complex disease. *Eur J Clin Invest* 2011; 41:1339-52.
22. Borish L, Culp JA. Asthma: a syndrome composed of heterogeneous diseases. *Ann Allergy Asthma Immunol* 2008; 101:1-8.
23. Hekking PP, Bel EH. Developing and emerging clinical asthma phenotypes. *J Allergy Clin Immunol Pract* 2014; 2:671-80.
24. Siroux V, Garcia-Aymerich. The investigation of asthma phenotypes. *Curr Opin Allergy Clin Immunol* 2011; 11:393-9.
25. Carlsen KCL, Pijnenburg M. Identification of asthma phenotypes in children. *Breathe* 2011; 8:38-44.
26. Stein RT, Martinez FD. Asthma phenotypes in childhood: lessons from an epidemiological approach. *Pediatr Respir Rev* 2004; 5: 155-61.

27. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med* 2010; 181:315-23.
28. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med* 2012; 18:716-25.
29. Gibson PG, McDonald VM, Marks GB. Asthma in older adults. *Lancet* 2010; 376:803-13.
30. de Nijs SB, Venekamp LN, Bel EH. Adult-onset asthma: is it really different? *Eur Respir Rev* 2013; 22:44-52.
31. Fingleton J, Travers J, Williams M, et al. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. *J Allergy Clin Immunol* 2015; 136:601-9.
32. Rönmark E, Andersson C, Nyström L, Forsberg B, Järvholm B, Lundbäck B. Obesity increases the risk for incident asthma among adults. *Eur Respir J* 2005; 25:282-8.
33. Brusselle GG, Kraft M. Trustworthy guidelines on severe asthma thanks for the ERS and ATS. *Eur Respir J* 2014; 43:315-8.
34. Ekerljung L, Bjerg A, Bossios A, et al. Five-fold increase in use of inhaled corticosteroids over 18 years in the general adult population in West Sweden. *Respir Med* 2014; 108:685-93.
35. Rönmark E, Lundbäck B, Jönsson E, Jonsson AC, Lindström M, Sandström T. Incidence of asthma in adults – report from the Obstructive Lung Disease in Northern Sweden Study. *Allergy* 1997; 52:1071-8.
36. Rönmark E, Jönsson E, Lundbäck B. Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study. *Thorax* 1999; 54:611-3.
37. Pallasaho P, Lindström M, Pölluste J, Loit HM, Sovijärvi A, Lundbäck B. Low socio-economic status is a risk factor for respiratory symptoms: a comparison between Finland, Sweden and Estonia. *Int J Tuberc Lung Dis* 2004; 8:1292-300.
38. Lindström M, Kotaniemi J, Jönsson E, Lundbäck B. Smoking, respiratory symptoms, and diseases: a comparative study between northern Sweden and northern Finland: report from the FinEsS study. *Chest* 2001; 119:852-61.
39. Burney PG, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. *Eur Respir J* 1994; 7:954-60.
40. Rönmark EP, Ekerljung L, Lötval J, Wennergren G, Rönmark E, Torén K, et al. Eczema among adults: prevalence, risk factors and relation to airway diseases – results from a large scale population survey in Sweden. *Br J Dermatol* 2012; 166: 1301-1308.
41. Lötval J, Ekerljung L, Lundbäck B. Multi-symptom asthma is closely related to nasal blockage, rhinorrhea and symptoms of chronic rhinosinusitis-evidence from the West Sweden Asthma Study. *Respir Res* 2010; 11:163.
42. Ekerljung L, Bossios A, Lötval J, et al. Multi-symptom asthma as an indication of disease severity in epidemiology. *Eur Respir J* 2011; 38:825-32.

43. Mincheva R, Ekerljung L, Bossios A, Lundbäck B, Lötval J. High prevalence of severe asthma in a large random population study. *J Allergy Clin Immunol* 2018; 141:2256-64.
44. Rönmark EP, Ekerljung L, Mincheva R, et al. Different risk factor patterns for adult asthma, rhinitis and eczema: results from West Sweden Asthma Study. *Clin Transl Allergy* 2016; 6:28.
45. Eriksson J, Ekerljung L, Lötval J, et al. Growing up on a farm leads to lifelong protection against allergic rhinitis. *Allergy* 2010; 65:1397-403.
46. Bjerg A, Ekerljung L, Eriksson J, et al. Increase in pollen sensitization in Swedish adults and protective effect of keeping animals in childhood. *Clin Exp Allergy* 2016; 46:1328-36.
47. Wennergren G, Ekerljung L, Alm B, Eriksson J, Lötval J, Lundbäck B. Asthma in late adolescence—farm childhood is protective and the prevalence increase has levelled off. *Pediatr Allergy Immunol* 2010; 21:806-13.
48. Eriksson J, Ekerljung L, Bossios A, et al. Aspirin-intolerant asthma in the population: prevalence and important determinants. *Clin Exp Allergy* 2015; 45:211-9.
49. Axelsson M, Cliffordson C, Lundbäck B, Lötval J. The function of medication beliefs as mediators between personality traits and adherence behavior in people with asthma. *Patient Prefer Adherence* 2013; 7:1101-9.
50. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010; 106:86-94.
51. Langhoff-Roos J, Krebs L, Klungsøyr K, et al. The Nordic medical birth registers – a potential goldmine for clinical research. *Acta Obstet Gynecol Scand* 2014; 93:132-7.
52. Gissler M, Louhiala P, Hemminki E. Nordic Medical Birth Registers in epidemiological research. *Eur J Epidemiol* 1997; 13:169-75.
53. Schnohr P, Jensen GB, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study. *Eur Heart J Suppl* 2011; 3:H1-83.
54. Vikse BE, Vollset SE, Tell GS, Refsum H, Iversen BM. Distribution and determinants of serum creatinine in the general population: the Hordaland Health Study. *Scand J Clin Lab Invest* 2004; 64:709-22.
55. Lundbäck B, Nyström L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in a postal survey. *Eur Respir J* 1991; 4:257-66.
56. Burney PG, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. *Eur Respir J* 1994; 7:954-60.
57. Mindell JS, Giampaoli S, Goesswald A, et al. Sample selection, recruitment and participation rates in health examination surveys in Europe – experience from seven national surveys. *BMC Med Res Methodol* 2015; 15:78.

1
2 517
3
4 518
5 519
6
7 520
8 521
9
10 522
11 523
12
13 524
14
15 525
16 526
17
18 527
19 528
20
21 529
22
23 530
24 531
25
26 532
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Phases and components of investigations in the West Sweden Asthma Study

Figure 2: Participants flow in the West Sweden Asthma Study

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Table 1. Baseline background characteristics of participants in the West Sweden Asthma Study (WSAS) by age and sex

WSAS I**										
	Frequency N = 18087 n (%)		≤30 years n = 3948 n (%)		31-45 years n = 4851 n (%)		46-60 years n = 4956 n (%)		61-75 years n = 4312 n (%)	
	Males n = 8190	Females n = 9897	Males n = 1695	Females n = 2253	Males n = 2169	Females n = 2682	Males n = 2297	Females n = 2659	Males n = 2027	Females n = 2285
Education level										
Less than high school	1817 (22.2)	2226 (22.5)	179 (10.6)	234 (10.4)	151 (7.0)	182 (6.8)	223 (9.3)	568 (21.4)	944 (46.6)	1236 (54.1)
High school	3385 (41.3)	3427 (34.6)	904 (53.3)	1068 (47.4)	1030 (47.5)	1019 (38.0)	1040 (40.8)	950 (35.7)	513 (25.3)	384 (16.8)
Tertiary education	2842 (34.7)	4063 (41.1)	568 (33.5)	922 (40.9)	960 (44.3)	1450 (54.1)	1034 (41.1)	1107 (41.6)	531 (26.2)	579 (25.3)
Missing information	146 (1.8)	181 (1.8)	44 (2.6)	29 (1.3)	28 (1.3)	31 (1.2)	11 (0.4)	34 (1.3)	39 (1.9)	86 (3.8)
Smoking status										
Non-smoker	5202 (63.5)	6227 (62.9)	1369 (80.8)	1650 (73.2)	1552 (71.5)	1801 (67.1)	1548 (63.5)	1426 (53.6)	1021 (50.4)	1343 (58.8)
Ex-smoker	1837 (22.4)	2139 (21.6)	97 (5.7)	203 (9.0)	330 (15.2)	497 (18.5)	299 (11.9)	778 (29.3)	741 (36.6)	655 (28.7)
Current smoker	1151 (14.0)	1531 (15.5)	229 (13.5)	400 (17.7)	287 (13.2)	384 (14.3)	669 (26.6)	455 (17.1)	265 (13.1)	287 (12.6)
Occupational exposure to gas, dust and fumes										
No	5587 (68.2)	8551 (86.4)	1250 (73.7)	1939 (86.1)	1498 (69.1)	2283 (85.1)	1316 (66.6)	2279 (85.7)	1306 (64.4)	2035 (89.1)
Yes	2603 (31.8)	1346 (13.6)	445 (26.2)	314 (13.9)	671 (30.9)	399 (14.9)	666 (26.3)	380 (14.3)	721 (35.6)	250 (10.9)
Raised on a farm										
No	7004 (85.5)	8526 (86.2)	1544 (91.1)	2091 (92.8)	1964 (90.5)	2443 (91.1)	1268 (83.8)	2223 (83.6)	1568 (77.4)	1757 (76.9)
Yes	1186 (14.5)	1371 (13.8)	151 (8.9)	162 (7.2)	205 (9.5)	239 (8.9)	711 (28.1)	436 (16.4)	459 (22.6)	528 (23.1)
Family history of allergy										
No	5746 (70.2)	6010 (60.7)	952 (56.2)	1054 (46.8)	1417 (65.3)	1510 (56.3)	1205 (47.2)	1731 (65.1)	1670 (82.4)	1704 (74.6)
Yes	2444 (29.8)	3887 (39.3)	743 (43.8)	1199 (53.2)	752 (34.7)	1172 (43.7)	992 (39.5)	928 (34.9)	357 (17.6)	581 (25.4)
WSAS II										
	Frequency N = 24534 n (%)		≤30 years n = 4209 n (%)		31-45 years n = 5502 n (%)		46-60 years n = 6957 n (%)		61-75 years n = 7866 n (%)	
	Males n = 11204	Females n = 13330	Males n = 1787	Females n = 2422	Males n = 2456	Females n = 3046	Males n = 3135	Females n = 3822	Males n = 3826	Females n = 4040
Education level										
Less than high school	2096 (18.7)	2152 (16.1)	210 (11.7)	220 (9.1)	145 (5.9)	147 (4.8)	448 (14.3)	352 (9.2)	1293 (33.8)	1433 (35.5)
High school	4700 (41.9)	4591 (34.4)	969 (54.2)	1160 (47.9)	944 (38.4)	878 (28.8)	1467 (46.8)	1564 (40.9)	1320 (34.5)	989 (24.5)

Tertiary education	4294 (38.3)	6415 (48.1)	591 (33.1)	1020 (42.1)	1343 (54.7)	1995 (65.5)	1911 (38.0)	1865 (48.8)	1169 (30.5)	1535 (38.0)
Missing information	114 (1.0)	172 (1.3)	17 (1.0)	22 (0.9)	24 (1.0)	26 (0.9)	29 (0.9)	41 (1.1)	44 (1.2)	83 (2.0)
Smoking status										
Non-smoker	7167 (64.0)	8585 (64.4)	1406 (78.7)	1865 (77.0)	1804 (73.5)	2226 (73.1)	2095 (66.8)	2336 (61.1)	1862 (48.7)	2158 (53.4)
Ex-smoker	2725 (24.3)	3109 (23.3)	134 (7.5)	201 (8.3)	376 (15.3)	537 (17.6)	64 (2.1)	974 (25.5)	1551 (40.5)	1397 (34.6)
Current smoker	1312 (11.7)	1636 (12.3)	247 (13.8)	356 (14.7)	276 (11.2)	283 (9.3)	77 (12.0)	512 (13.4)	413 (10.8)	485 (12.0)
Occupational exposure to gas, dust and fumes										
No	8147 (72.7)	11923 (89.4)	1385 (77.5)	2161 (89.2)	1865 (75.9)	2732 (89.7)	2078 (72.0)	3425 (89.6)	2639 (69.0)	3605 (89.2)
Yes	3057 (27.3)	1407 (10.6)	402 (22.5)	261 (10.8)	591 (24.1)	314 (10.3)	81 (28.0)	397 (10.4)	1187 (31.0)	435 (10.8)
Raised on a farm										
No	9892 (88.3)	11814 (88.6)	1651 (92.4)	2257 (93.2)	2272 (92.5)	2768 (90.9)	2088 (89.8)	3424 (89.6)	3155 (82.5)	3365 (83.3)
Yes	1312 (11.7)	1516 (11.4)	136 (7.6)	165 (6.8)	184 (7.5)	278 (9.1)	241 (10.2)	398 (10.4)	671 (17.5)	675 (16.7)
Family history of allergy										
No	7711 (68.8)	8041 (60.3)	928 (51.9)	1107 (45.7)	1514 (61.6)	1624 (53.3)	2088 (69.5)	2334 (61.1)	3090 (80.8)	6066 (77.1)
Yes	3492 (31.2)	5289 (39.7)	859 (48.1)	1315 (54.3)	942 (38.4)	1422 (46.7)	911 (30.5)	1488 (38.9)	736 (19.29)	1800 (22.9)

**20 participants had missing information for age and were therefore excluded from age-stratified analyses

Tables 2. Key results of risk factors for asthma, allergic rhinitis, and atopic eczema reported from the West Sweden Asthma Study (WSAS I)

Risk factor	Adjusted estimates ¹		
	Current asthma ² OR (95% CI)	Current allergic rhinitis ³ OR (95% CI)	Current eczema ⁴ OR (95% CI)
Female gender ⁵	1.77 (1.15-2.70)	0.91 (0.69-1.21)	1.71 (1.17-2.51)
Family history of asthma and allergic rhinitis ⁵			
None	1	1	1
Asthma only	1.29 (0.55-3.04)	0.61 (0.34-1.10)	1.45 (0.72-2.94)
Allergic rhinitis only	1.16 (0.66-2.03)	2.58 (1.79-3.72)	1.25 (0.77-2.04)
Both asthma and allergic rhinitis	4.33 (2.57-7.30)	2.76 (1.77-4.31)	1.61 (0.94-2.76)
Raised on a farm ^{5,6}	0.96 (0.52-1.77)	0.64 (0.42-0.96)	0.51 (0.27-0.99)
Body mass index			
Normal (20-25 kg/m ²)	1	1	1
Underweight (<20 kg/m ²)	0.95 (0.36-2.55)	1.42 (0.74-2.71)	1.00 (0.44-2.30)
Overweight (25-30 kg/m ²)	1.04 (0.65-1.67)	1.04 (0.77-1.41)	1.02 (0.68-1.54)
Obese (>30 kg/m ²)	1.95 (1.13-3.36)	2.30 (1.53-3.46)	1.34 (0.80-2.24)
Number of siblings			
0	1	1	1
1	3.09 (1.25-7.63)	1.16 (0.74-1.81)	0.72 (0.42-1.24)
2 or more	2.51 (1.02-6.15)	1.15 (0.74-1.79)	0.55 (0.32-0.94)
Allergic sensitization ^{5,7}	4.11 (2.71-6.25)	5.11 (3.77-6.93)	1.26 (0.85-1.85)
Exposure to gas, dust or fumes at work	1.85 (1.20-2.87)	1.03 (0.76-1.41)	2.08 (1.40-3.08)

¹Respective to each outcome, the estimates adjusted for age, gender, family history of asthma and rhinitis, exposure to gas and gas fumes at work place, body mass index, number of siblings, daycare attendance during childhood, and being raised on a farm

²Current asthma was defined as follows: ever had asthma or ever diagnosed with asthma by a physician and at least one of: reported use of asthma medication, or recurrent wheeze, or attacks of shortness of breath during the last 12 months.

³Allergic rhinitis was defined as follows: having had sneezing, runny nose or nasal blocking apart from colds during the last 12 months and having these nasal symptoms occurred simultaneously with itching and running eyes"


⁴Defined as having ever had recurrent itchy rash for at least 6 months and having had itchy rash during the last 12 months

⁵Reported in Rönmark EP et al. Different risk factor patterns for adult asthma, rhinitis and eczema: results from West Sweden Asthma Study. *Clin Transl Allergy* 2016; 6:28.


⁶Reported in Eriksson J, et al. Growing up on a farm leads to lifelong protection against allergic rhinitis. *Allergy* 2010; 65: 1397-1403.

⁷Allergic sensitization defined as serum immunoglobulin E to ImmunoCAP® Phadiatop ≥0.35 KU/1 to at least one of the following 11 airborne allergens: timothy grass, birch, mugwort, olive, parietaria, cat, dog, horse, D. pteronyssinus, D. farinae, and C. herbarum.

bmjopen-2018-027808 on 19 June 2019. Downloaded from <http://bmjopen.bmj.com/> on June 11, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES). All rights reserved. No reuse allowed without permission.



WSAS I



WSAS II

